Item 8. Financial Statements and Supplementary Data
ITEM 8. FINANCIAL STATEMENTS
AND SUPPLEMENTARY DATA.
Index to Financial Statements
Page
Report of Independent Registered Public Accounting Firm (PCAOB No. 577 )
F-1
Balance Sheets at June 30, 2026 and 2025
F-3
Statements of Operations for the Years Ended June 30, 2026 and 2025
F-4
Statements of Stockholders’ Equity for the Years Ended June 30, 2026 and 2025
F-5
Statements of Cash Flows for the Years Ended June 30, 2026 and 2025
F-6
Notes to Financial Statements
F-7
22
Report of Independent Registered Public Accounting
Firm
To the Board of Directors and
Stockholders of Precision Optics Corporation, Inc.
Opinion on the Financial Statements
We have audited the accompanying balance sheets
of Precision Optics Corporation, Inc. (the “Company”) as of June 30, 2026 and 2025, and the related statements of operations,
stockholders’ equity, and cash flows for each of the years in the two year period ended June 30, 2026, and the related notes (collectively
referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects,
the financial position of the Company as of June 30, 2026 and 2025, and the results of its operations and its cash flows for each of the
years in the two year period ended June 30, 2026, in conformity with accounting principles generally accepted in the United States of
America.
Basis for Opinion
These financial statements are the responsibility
of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our
audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (PCAOB) and are required to be independent
with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities
and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the
standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged
to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding
of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s
internal control over financial reporting. Accordingly, we express no such opinion.
Our audits included performing procedures to assess
the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond
to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating
the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
Critical Audit Matters
The critical audit matters communicated below
is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to
the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our
especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion
on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions
on the critical audit matters or on the accounts or disclosures to which they relate.
Revenue Recognition — Refer to Note
1B to the Financial Statements
Critical Audit Matter Description
The Company recognizes revenue upon transfer of
control of promised products to customers in an amount that reflects the consideration the Company expects to receive in exchange for
those products. The Company may enter into certain customer contracts that contain unique, customer-specific terms and conditions, variable
consideration, as well as multiple performance obligations. For such contracts, significant interpretation may be required to determine
the appropriate accounting, including the identification of performance obligations, the allocation of the transaction price to performance
obligations in the arrangement, the timing of the transfer of control of promised goods for each of those performance obligations, estimates
of variable consideration and agent versus principal consideration.
F- 1
Our assessment of managements’ evaluation
of the above referenced matters related to proper revenue recognition is significant to our audit because of the nature and extent of
audit effort required to address the matter, the amounts are material to the financial statements, the assessment process involves significant
auditor judgment, and the application of U.S. generally accepted accounting principles in this area is complex.
How the Critical Audit Matter Was Addressed in the Audit
Our principal audit procedures related to the
Company’s revenue recognition for customer contracts included the following:
·
We evaluated the appropriateness of management’s revenue recognition policies.
·
We tested the mathematical accuracy of management’s calculations of revenue and the associated timing of revenue recognized in the financial statements.
·
We selected a sample of revenue transactions and performed the following procedures:
o
Obtained and read source documents for each selection, including master agreements, purchase orders and other documents that evidenced the customer arrangement.
o
Tested management’s identification and treatment of the key contract terms, including performance obligations and variable consideration.
o
Assessed the terms in the customer agreement and evaluated the appropriateness of management’s application of the Company’s accounting policies, along with their use of estimates, in the determination of revenue recognition conclusions.
/s/ Stowe & Degon LLC
Westborough, Massachusetts
September 28, 2026
We have served as the Company’s auditor
since 2008
F- 2
PRECISION OPTICS CORPORATION, INC.
Balance Sheets at June 30, 2026 and 2025
2026
2025
ASSETS
Current Assets:
Cash and cash equivalents
$ 9,841,142
$ 1,773,735
Accounts receivable, net of allowance for credit losses of $ 108,220 at June 30, 2026 and $ 80,192 at June 30, 2025
5,944,412
4,336,730
Inventories, net
3,829,414
3,562,112
Prepaid expenses
494,488
385,390
Total current assets
20,109,456
10,057,967
Fixed Assets:
Machinery and equipment
3,410,813
3,385,958
Leasehold improvements
1,226,171
871,356
Furniture and fixtures
645,046
538,428
Total fixed assets
5,282,030
4,795,742
Less—Accumulated depreciation and amortization
4,394,317
4,261,950
Net fixed assets
887,713
533,792
Operating lease right-of-use asset
2,300,866
141,825
Patents, net
212,889
232,493
Goodwill
8,824,210
8,824,210
Total other assets
11,337,965
9,198,528
TOTAL ASSETS
$ 32,335,134
$ 19,790,287
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities:
Current portion of capital lease obligation
$ –
$ 27,368
Current maturities of long-term debt
577,898
577,898
Accounts payable
3,582,674
2,909,100
Customer advances
2,498,501
1,821,929
Accrued compensation and other
1,843,368
764,004
Current portion of operating lease liabilities
325,500
50,995
Total current liabilities
8,827,941
6,151,294
Long-term debt, net of current maturities
711,305
1,289,205
Operating lease liability, net of current portion
2,446,576
90,954
Total liabilities
11,985,822
7,531,453
Stockholders’ Equity:
Common stock, $ 0.01 par value: 50,000,000 shares authorized; issued and outstanding – 10,972,792 shares at June 30, 2026 and 7,714,701 shares at June 30, 2025
109,728
77,147
Additional paid-in capital
80,840,105
69,152,317
Accumulated deficit
( 60,600,521 )
( 56,970,630 )
Total stockholders’ equity
20,349,312
12,258,834
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY
$ 32,335,134
$ 19,790,287
The accompanying notes are an integral part
of these financial statements.
F- 3
PRECISION OPTICS CORPORATION, INC.
Statements of Operations
for the Years Ended June 30, 2026 and 2025
2026
2025
Revenues
$ 31,531,765
$ 19,091,269
Cost of goods sold
26,100,545
15,686,836
Gross profit
5,431,220
3,404,433
Research and development expenses, net
1,033,156
1,157,963
Selling, general and administrative expenses
7,906,672
7,797,761
Total operating expenses
8,939,828
8,955,724
Operating loss
( 3,508,608 )
( 5,551,291 )
Other income (expense):
Interest expense
( 148,129 )
( 227,019 )
Interest income
31,804
–
Loss before provision for income taxes
( 3,624,933 )
( 5,778,310 )
Provision for income taxes
4,958
1,936
Net loss
$ ( 3,629,891 )
$ ( 5,780,246 )
Loss per share:
Basic and fully diluted
$ ( 0.43 )
$ ( 0.85 )
Weighted average common shares outstanding:
Basic and fully diluted
8,530,599
6,790,466
The accompanying notes are an integral part
of these financial statements.
F- 4
PRECISION OPTICS CORPORATION, INC.
Statements of Stockholders’ Equity
for the Years Ended June 30, 2026 and 2025
Number of
Shares
Common
Stock
Additional
Paid-in
Capital
Accumulated
Deficit
Total
Stockholders’
Equity
Balance, June 30, 2024
6,073,939
$ 60,739
$ 61,197,433
$ ( 51,190,384 )
$ 10,067,788
Issuance of common stock in a registered direct offering
1,538,368
15,384
6,254,752
–
6,270,136
Proceeds from exercise of stock option
71,979
721
88,329
–
89,050
Issuance of common stock for consulting services and employees
30,415
303
151,395
–
151,698
Stock-based compensation
–
–
1,460,408
–
1,460,408
Net loss
–
–
–
( 5,780,246 )
( 5,780,246 )
Balance, June 30, 2025
7,714,701
$ 77,147
$ 69,152,317
$ ( 56,970,630 )
$ 12,258,834
Issuance of common stock in public offering
3,194,444
31,944
10,598,734
–
10,630,678
Proceeds from exercise of stock option
40,294
404
39,595
–
39,999
Issuance of common stock for employee services
23,353
233
100,267
–
100,500
Stock-based compensation
–
–
949,192
–
949,192
Net loss
–
–
–
( 3,629,891 )
( 3,629,891 )
Balance, June 30, 2026
10,972,792
$ 109,728
$ 80,840,105
$ ( 60,600,521 )
$ 20,349,312
The accompanying notes are an integral part
of these financial statements.
F- 5
PRECISION OPTICS CORPORATION, INC.
Statements of Cash Flows
For the Years Ended June 30, 2026 and 2025
2026
2025
Cash Flows from Operating Activities:
Net loss
$ ( 3,629,891 )
$ ( 5,780,246 )
Adjustments to reconcile net loss to net cash (used in) provided by operating activities-
Depreciation and amortization
279,277
212,439
Stock-based compensation expense
1,139,692
1,612,106
Non-cash legal expense
–
34,881
Non-cash interest expense
18,433
11,563
Non-cash operating lease expense
252,336
124
Loss on disposal of fixed assets
34,506
–
Changes in operating assets and liabilities:
Accounts receivable, net
( 1,607,682 )
( 791,239 )
Inventories
( 267,302 )
( 694,012 )
Prepaid expenses
( 109,098 )
( 86,026 )
Accounts payable
673,574
1,511,787
Contract liabilities
676,572
649,579
Accrued compensation and other
989,364
( 76,658 )
Net cash used in operating activities
( 1,550,219 )
( 3,395,702 )
Cash Flows from Investing Activities:
Additional patent costs
( 5,564 )
( 6,264 )
Proceeds from sale of fixed assets
3,000
–
Purchases of property and equipment
( 426,786 )
( 227,209 )
Net cash used in investing activities
( 429,350 )
( 233,473 )
Cash Flows from Financing Activities:
Payment of capital lease obligations
( 27,368 )
( 41,114 )
Principal payments of long-term debt
( 596,333 )
( 280,440 )
Payment of debt issuance costs
–
( 40,000 )
Repayments on line of credit
–
( 1,000,000 )
Gross proceeds from registered direct offerings of common stock
–
6,270,136
Proceeds from public offering of common stock, net
10,630,678
–
Gross proceeds from exercise of stock options
39,999
89,050
Net cash provided by financing activities
10,046,976
4,997,632
Net increase in cash and cash equivalents
8,067,407
1,368,457
Cash and cash equivalents, beginning of year
1,773,735
405,278
Cash and cash equivalents, end of year
$ 9,841,142
$ 1,773,735
Supplemental disclosure of cash flow information:
Cash paid during the year for income taxes
$ 2,600
$ 1,936
Cash paid during the year for interest
$ 129,696
$ 216,456
Leasehold improvements financed by landlord
$ 218,750
$ –
Issuance of common stock for consulting and employee services
$ 100,500
$ 151,698
Stock based compensation for employee services included in accrued compensation
and other
90,000
–
Operating right-of-use assets obtained in exchange for operating lease liabilities
$ 2,632,584
$ 133,650
The accompanying notes are an integral part
of these financial statements.
F- 6
PRECISION OPTICS CORPORATION, INC.
Notes to Financial Statements
(1)
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
(a)
Nature of Business
Precision Optics Corporation, Inc. (the “Company”)
designs, develops, manufactures and sells specialized optical and illumination systems and related components. The Company conducts business
in one industry segment only and its customers are primarily domestic. The Company performs advanced optical and illumination system design,
development, assembly and manufacturing services, and sources for resale specialized optical components for products that fall into two
principal areas: (i) medical products for use by hospitals and physicians; and (ii) products used by defense contractors, aerospace and
industrial customers.
(b)
Revenues
The Company determines revenue recognition for
arrangements that we determine are within the scope of Accounting Standards Codification Topic 606, Revenue from Contracts with Customers ,
(“ASC 606”), by performing the following five steps: (i) identify the contract with a customer; (ii) identify the performance
obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations
in the contract; and (v) recognize revenue when, or as, we satisfy the performance obligations. At contract inception, once the contract
is determined to be within the scope of ASC 606, we assess the goods or services promised within the contract and determine those that
are performance obligations and assess whether each promised good or service is distinct based on the contract.
The Company disaggregates revenues by product
and service types as it believes best depicts how the nature, amount, timing and uncertainty of revenues and cash flows are affected by
economic factors. Revenues are comprised of the following for year ended June 30, 2026, and 2025:
Schedule of disaggregation of revenues
Year Ended June 30,
2026
2025
Engineering Design Services
$ 3,473,640
$ 4,938,158
Systems Manufacturing
22,628,047
8,290,225
Micro Optics Lab
519,540
2,135,562
Ross Optical Industries
4,910,538
3,727,324
Total Revenues
$ 31,531,765
$ 19,091,269
Selling costs to obtain and fulfill contracts
are expensed as incurred due to the short-term nature of a majority of contracts. The Company extends terms of payment to its customers
based on commercially reasonable terms for the markets of its customers, while also considering their credit quality. Shipping and handling
costs charged to customers are included in revenue.
At June 30, 2026, and 2025, two individual
customers accounted for more than 10 % of the Company’s total revenue.
Revenue recognition policies for each of the three
product and service types appear below.
F- 7
Engineering Design Services
The Company enters into contractual agreements
with our customers, including design services agreements, statements of work and receive purchase orders for development projects. These
agreements provide costs on an estimated basis for the services we have agreed to provide. Engineering Design Services are rendered on
a time and materials basis. The Company recognizes revenue as customers are invoiced for the actual engineering services provided in the
period. Revenue is also recognized on materials purchased for development projects at the time of receipt. Engineering Design Services
are provided on a best-efforts basis; no warranty is provided as there is no guarantee that the work will result in the attainment of
the customer’s project objectives. The Company may obtain customer deposits in advance of rendering engineering design services.
Customer deposits are treated as contractual liabilities until the terms of customer agreements are satisfied and are not a component
of revenue.
Systems Manufacturing, Micro Optics Laboratory,
Ross Optical Industries
The Company provides fixed price quotations to
our customers and requires purchase orders for items manufactured and distributed through the Systems Manufacturing, Micro Optics Laboratory
and Ross Optical Industries business units. Revenue is recognized at the time title passes to our customer based on our review of the
customer contract, generally at the time of shipment from our facilities. Occasionally the Company may enter into “bill and hold”
contractual arrangements where title is held by our customers while goods are stored at our facilities for their convenience.
Contract Assets and Liabilities
The nature of the Company’s products and
services does not generally give rise to contract assets as it typically does not incur costs to fulfill a contract before a product or
service is provided to a customer. The Company’s costs to obtain contracts are typically in the form of sales commissions paid to
employees. The Company has elected to expense sales commissions associated with obtaining a contract as incurred as the amortization period
is generally less than one year. These costs have been recorded in selling, general and administrative expenses. As of June 30, 2026 and
2025, there were no contract assets recorded in the Company’s Balance Sheets.
The Company’s contract liabilities arise
as a result of unearned revenue received from customers at inception of contracts or where the timing of billing for services precedes
satisfaction of performance obligations. The Company generally satisfies performance obligations within one year from the contract inception
date.
Contract liabilities, which were recorded as customer
advances in the Company’s Balance Sheets, and unearned revenue are comprised of the following:
Schedule of contract liabilities
Year Ended June 30,
2026
2025
Contract liabilities, beginning of period
$ 1,821,929
$ 1,172,350
Unearned revenue received from customers
2,278,058
1,364,332
Revenue recognized
( 1,601,486 )
( 714,753 )
Contract liabilities, end of period
$ 2,498,501
$ 1,821,929
F- 8
(c)
Cash and Cash Equivalents
The Company includes in cash equivalents all highly
liquid investments with original maturities of three months or less at the time of acquisition. Cash and cash equivalents of $ 9,841,142
and $ 1,773,735 on June 30, 2026 and 2025, respectively, consist primarily of cash at banks and money market funds. The Company maintains
its cash and cash equivalents in bank deposit accounts that, at times, may exceed federally insured limits. The Company has not experienced
any losses in such accounts. The Company believes it is not exposed to any significant credit risk on its cash and cash equivalents.
(d)
Inventories
Inventories are stated at the lower of cost (first-in,
first-out) and net realizable value and include material, labor and manufacturing overhead. The components of inventories on June 30,
2026 and 2025 are as follows:
Schedule of inventory
2026
2025
Raw material
$ 2,043,446
$ 1,799,624
Work-in-progress
570,360
598,720
Finished goods
1,215,608
1,163,768
Total Inventories (Net)
$ 3,829,414
$ 3,562,112
The Company provides for estimated obsolescence
on unmarketable inventory based upon assumptions about future demand and market conditions. If actual demand and market conditions are
less favorable than those projected by management, additional inventory write-downs may be required. Inventory, once written down, is
not subsequently written back up, as these adjustments are considered permanent adjustments to the carrying value of the inventory. The
reserve for excess and obsolete inventory for the years ended June 30, 2026 and 2025, were $ 330,965 and $ 272,894 , respectively.
(e)
Fixed Assets
Fixed assets are recorded at cost. Maintenance
and repair items are expensed as incurred. The Company provides for depreciation and amortization by charges to operations, using the
straight-line and declining-balance methods, which allocate the cost of fixed assets over the following estimated useful lives:
Schedule of estimated useful lives
Asset Classification
Estimated Useful Life
Machinery and equipment
2-7 years
Leasehold improvements
Shorter of lease term or estimated useful life
Furniture and fixtures
5 years
Depreciation expense was $ 254,109 and $ 186,990
for the years ended June 30, 2026 and 2025, respectively.
F- 9
(f)
Significant Customers and Concentration of Credit Risk
Financial instruments that subject the Company
to credit risk consist primarily of cash equivalents and trade accounts receivable. The Company places its investments with highly rated
financial institutions. The Company has not experienced any losses on these investments to date. At June 30, 2026, and 2025, two
individual customers accounted for more than 10 % of the Company’s total accounts receivable.
The allowance for credit losses was $ 108,220 at
June 30, 2026, and $ 80,192 at June 30, 2025.
Schedule of allowance for credit losses
Year Ended June 30,
2026
2025
Allowance for credit losses, beginning of period
$ 80,192
$ 118,872
Change in the provision for expected credit losses
39,092
( 44,858 )
Writeoffs charged against the allowance
( 11,064 )
6,178
Allowance for credit losses, end of period
$ 108,220
$ 80,192
The Company generally does not require collateral
or other security as a condition of sale, rather it relies on credit approval, balance limitation and monitoring procedures to control
credit risk in trade account financial instruments. Management believes the allowance for credit losses, which is established based upon
review of specific account balances and historical experience, is adequate at June 30, 2026.
(g)
Loss per Share
Basic income (loss) per share is computed by dividing
net income or net loss by the weighted average number of shares of common stock outstanding during the period. Diluted income (loss) per
share is computed by dividing net income or net loss by the weighted average number of shares of common stock outstanding during the period,
plus the number of potentially dilutive securities outstanding during the period such as stock options and warrants. For the years ended
June 30, 2026 and 2025, the effect of such securities was antidilutive and not included in the diluted calculation because of the net
loss generated in those periods.
The following is the calculation of loss per share
for the years ended June 30, 2026 and 2025:
Schedule of loss per share
Year Ended June 30,
2026
2025
Net Loss– Basic and Diluted
$ ( 3,629,891 )
$ ( 5,780,246 )
Basic and diluted weighted average shares outstanding
8,530,599
6,790,466
Loss per share
Basic and fully diluted
$ ( 0.43 )
$ ( 0.85 )
The number of shares issuable upon the exercise
of outstanding stock options and warrants that were excluded from the computation as their effect was antidilutive was approximately 1,659,909
and 1,623,576 for the years ended June 30, 2026 and 2025, respectively.
F- 10
(h)
Stock-Based Compensation
The measurement and recognition of compensation
costs for all stock-based awards made to employees and the Board of Directors are based upon fair value over the requisite service period
for awards expected to vest. The Company estimates the fair value of share-based awards on the date of grant using the Black-Scholes option-pricing
model. Stock-based compensation costs recognized for the years ended June 30, 2026, and 2025 amounted to $ 1,139,692 and $ 1,612,106 , respectively.
(i)
Goodwill and Patents
Long-lived assets such as goodwill and patents
are capitalized when acquired and reviewed for impairment on an annual basis or whenever events or changes in circumstances indicate that
the book value of the asset may not be recoverable. Impairment of the carrying value of long-lived assets such as goodwill and patents
would be indicated if the best estimate of future undiscounted cash flows expected to be generated by the asset grouping is less than
its carrying value. If an impairment is indicated, any loss is measured as the difference between estimated fair value and carrying value
and is recognized in operating income or loss. Assets to be disposed of are reported at the lower of the carrying amount or fair value
less costs to sell. No such impairments of goodwill or patents have been estimated by management during the years ended June 30, 2026
or 2025. Amortization expense for the year ended June 30, 2026 and 2025 was $ 25,168 and $ 25,448 , respectively.
(j)
Fair Value of Financial Instruments
Financial instruments consist principally of cash
and cash equivalents, accounts receivable and accounts payable. The estimated fair value of these financial instruments approximates their
carrying value due to their short-term nature.
(k)
Research and Development
Research and development expenses are charged
to operations as incurred. The Company groups development and prototype costs and related reimbursements in research and development.
There were no reimbursements for research and development recorded in research and development for the years ended June 30, 2026, and
2025.
(l)
Comprehensive Income
Comprehensive income or loss is defined as the
change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources.
The Company’s comprehensive loss or income for the years ended June 30, 2026 and 2025 was equal to its net loss for the same periods.
(m)
Income Taxes
Income taxes are accounted for under the asset
and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between
the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax
credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in
the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities
of a change in tax rates is recognized in income in the period that includes the enactment date. In assessing the likelihood of utilization
of existing deferred tax assets, management has considered historical results of operations and the current operating environment.
F- 11
(n)
Segment Reporting
Operating segments are identified as components
of an enterprise for which separate discrete financial information is available and is regularly reviewed by the chief operating decision
maker (“CODM”) in making decisions regarding resource allocation and assessing performance. The Company’s CODM is its
Chief Executive Officer.
The Company operates as a single reportable segment.
The CODM assesses the Company’s performance and allocates resources based on the Company’s results of operations, including
the revenues and expenses presented in the statements of operations. The CODM uses net income (loss) as the measure of segment profit
or loss in evaluating the Company’s operating performance and making resource allocation decisions.
(o)
Use of Estimates
The preparation of financial statements in conformity
with accounting standards generally accepted in the United States requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements
and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
(p)
Recent Accounting Pronouncements
In December 2023, the FASB issued ASU 2023-09,
Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”), which enhances income tax disclosure requirements,
primarily related to the rate reconciliation and income taxes paid. The Company adopted ASU 2023-09 effective July 1, 2025. The adoption
of ASU 2023-09 resulted in additional disclosures within the Company’s consolidated financial statements and did not have a material
impact on the Company’s financial statements.
In November 2024, the FASB issued ASU 2024-03,
Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income
Statement Expenses (“ASU 2024-03”), which requires additional disclosures about certain expenses included in the expense captions
presented on the statement of operations. The guidance is effective for annual reporting periods beginning after December 15, 2026, and
interim reporting periods within annual reporting periods beginning after December 15, 2027, with early adoption permitted. The Company
is currently evaluating the impact of adopting this guidance on its financial statement disclosures.
In December 2025, the FASB issued ASU 2025-10,
Government Grants (Topic 832): Accounting for Government Grants Received by Business Entities (“ASU 2025-10”). ASU 2025-10
adds guidance on the recognition, measurement and presentation of government grants. ASU 2025-10 is effective for fiscal years beginning
after December 15, 2028, including interim periods within those fiscal years, and permits modified prospective, modified retrospective,
or full retrospective adoption. The Company has elected to early adopt the guidance effective for the fiscal year ended June 30, 2026.
(q)
Government Grants
The Company recognizes grants or subsidies from
governments as a receivable when it is probable that the Company will comply with any conditions associated with the grant arrangement
and the grant will be received. The Company evaluates the conditions of each grant as of each reporting period to determine whether it
is probable that the Company has met the conditions of each grant arrangement. Grants are recognized in the statements of operations on
a systematic basis over the periods in which the Company recognized the related costs for which the grant is intended to compensate. The
Company records grant receivables in the balance sheets in accounts receivable, depending on when the amounts are expected to be received
from the government agency.
During the year ended June 30, 2026, the Company
recognized a reduction to expense of $ 224,544 related to grants within the statements of operations, all in cost of goods sold. As of
June 30, 2026, the Company has $ 224,544 recorded as a government receivable, included in accounts receivable, which relates to personnel,
direct costs and operating expenses to be reimbursed and received as cash. As of June 30, 2025, the Company had no government receivable.
F- 12
(r)
Derivative Financial Instruments
The Company evaluates warrants and other financial
instruments to determine whether such instruments or embedded features qualify as derivatives to be accounted for separately in accordance
with ASC 480, Distinguishing Liabilities from Equity , and ASC 815, Derivatives and Hedging . Warrants that do not meet the
criteria for equity classification are recorded as liabilities at fair value and are remeasured at each reporting date until exercised,
expired, modified, or otherwise settled. Changes in the fair value of warrant liabilities are recognized in other income (expense), net
in the statements of operations.
Warrants that meet the criteria for equity classification,
including the scope exception under ASC 815-10-15-74(a), are classified within stockholders’ equity and are not subsequently remeasured
as long as the conditions for equity classification continue to be met.
The Company reassesses the classification of warrants
at each reporting date. As of June 30, 2026, the Company determined that all outstanding warrants qualified for equity classification.
(s)
Reclassifications
Certain items in the 2025 financial statements
have been reclassified to conform to the current year classifications. Such classifications have no effect on previously reported loss
from operations or net loss.
(t)
IEEPA Tariff Refunds and Related Customer Refunds
On February 20, 2026, the U.S. Supreme Court issued a ruling relating
to tariffs imposed under the International Emergency Economic Powers Act (“IEEPA”). Following the ruling, the U.S. Customs and
Border Protection and other federal agencies issued additional guidance and took actions affecting the assessment, collection, refund,
and/or protest of certain tariffs. In March 2026, the U.S. Court of International Trade issued an additional ruling stating that importers
that have paid tariffs under IEEPA are due refunds.
Accordingly, during the year ended June 30, 2026,
the Company recorded a receivable of $ 880,598 within accounts receivable in the balance sheet, representing recovery of IEEPA tariffs
previously paid, with a corresponding offset to cost of goods sold. In addition, the Company recorded a $ 558,266 liability within accrued
compensation and other in the balance sheet as a result of its decision to refund IEEPA tariff surcharges collected from customers, with
a corresponding reduction of revenue in the statement of operations. In the year ended June 30, 2026, we received $ 37,576 in IEEPA tariff
refund proceeds, resulting in outstanding IEEPA tariff refund claims receivable of $ 843,022 within “accounts receivable” in
the balance sheet, representing a recovery of IEEPA tariffs previously paid.
(2)
COMMITMENTS
(a)
Bank Financing Activities
Bank Term Loan and Line of Credit
On October 4, 2021, the Company entered into a
Loan Agreement with Main Street Bank of Marlborough, Massachusetts (the “Lender”), which provided for a $ 2,600,000 Term Loan
and a $ 250,000 Revolving Line of Credit Loan Facility (the “Revolver”), which was increased to $ 500,000 effective May 17,
2022, and $ 1,250,000 effective June 2, 2023. Borrowings under the Revolver are limited by the borrowing base comprised of a percentage
of accounts receivable and inventory and secured by all assets of the Company. Borrowings under the Revolver bear interest payable monthly
at the prime lending rate plus 1.5% per annum and shall not be less than 4.75% per annum. Borrowings under the Revolver are due upon demand.
There were no borrowings under the Revolver at June 30, 2026.
F- 13
The Company’s Loan Agreement with the Lender
contains a minimum annual debt service coverage ratio covenant of 1.2x. The Company did not meet this annual debt service coverage ratio
for the fiscal year ended June 30, 2024. The Company’s Lender agreed to waive compliance with such debt service ratio covenant for
the period ending June 30, 2024. In addition to such waiver, the Lender and the Company entered into an amendment dated September 30,
2024 to that certain Term Loan dated October 4, 2021, as amended and that certain Promissory Note dated June 2, 2023 (collectively, the
“Notes”) which amendments provided for a six-month period of interest only payments from October 15, 2024 through March 15,
2025 for the Notes. The Company commenced payments of principal and interest under the Notes beginning with the payments due on April
15, 2025, with a new amortization schedule for the remaining term for such Notes through their maturity date. On February 14, 2025, the
Lender agreed to waive compliance with the annual debt service coverage ratio covenant for the fiscal year ending June 30, 2025, subject
to a $30,000 waiver fee and the completion of an equity raise of at least $4,500,000 by February 24, 2025, which the Company satisfied
on February 21, 2025. Any future advances are contingent on the Company achieving a minimum Debt Service Coverage ratio of 1.20x based
on quarterly testing, which the Company was not in compliance with as of June 30, 2026.
On September 25, 2026, the lender agreed to waive
the Company’s minimum annual debt service coverage ratio covenant for the fiscal year ended June 30, 2026 and modified the Company’s
credit arrangements to eliminate the debt service coverage ratio covenant and replace it with a minimum liquidity covenant of $2.0 million,
retain the existing term note, and provide the Company access to $750,000 of availability under its revolving line of credit, subject
to borrowing-base requirements and a $5,000 waiver fee. The lender further agreed expand availability under the revolving line of credit
to $1,250,000 upon attaining a DSCR of 1.2x. There were no other changes to or modifications to the Loan Agreement or the Notes.
Long-Term Debt
Long-term debt consists of the following at June
30, 2026 and 2025:
Schedule of long-term debt
2026
2025
Term Loan Note payable to Main Street Bank with monthly principal payments of $ 35,271 , excluding six months in Fiscal 2025, plus interest at a fixed rate of 7.0 % per annum. Secured by all assets of the Company, and subject to certain periodic reporting to the bank and other conditions including an annual minimum EBITDA plus stock-based compensation to debt service coverage ratio of 1.20:1 commencing with the fiscal year ending June 30, 2023. The Term Loan Note matures on October 15, 2028 .
$ 987,597
$ 1,410,853
Permanent Working Capital Loan payable to Main Street Bank with monthly principal payments of $ 14,423 , excluding six months in Fiscal 2025, plus interest at a fixed rate of 8.625 % per annum. Secured by all assets of the Company, and subject to certain periodic reporting to the bank and other conditions including an annual minimum EBITDA plus stock-based compensation to debt service coverage ratio of 1.20:1 commencing with the fiscal year ending June 30, 2023. The Permanent Working Capital Loan matures on June 15, 2028 .
346,154
519,231
Less current maturities
( 577,898 )
( 577,898 )
Less debt issuance costs, net of accumulated amortization of $ 48,187 and $ 29,756 , respectively.
( 44,548 )
( 62,981 )
Long-term debt, net of current portion of debt issuance costs
$ 711,305
$ 1,289,205
F- 14
At June 30, 2026 principal payments due
on long-term debt are as follows:
Schedule of principal payments
Fiscal Year Ending June 30:
2027
$ 596,333
2028
596,333
2029
141,085
Total long-term debt
$ 1,333,751
(b)
Lease Obligation
In March 2021 the Company entered into a five-year
capital lease in the amount of $ 161,977 and in January 2020, the Company entered into a five-year capital lease for $ 47,750 , both for
manufacturing equipment. The net book value of fixed assets under capital lease obligations as of June 30, 2026 is $ 0 .
On July 1, 2019 the Company entered into a three-year
operating lease for its facility in El Paso, Texas, and in February 2022 the Company entered into an extension of the lease for an additional
three years through June 2025. In May 2025, this lease was extended for an additional three years through May 2028. Remaining minimum
lease payments at June 30, 2026 total $ 98,687 . Total lease costs including base rent and common area expenses was $ 73,085 and $ 67,552
during the fiscal years ended June 30, 2026 and 2025, respectively. The amount of variable lease payments is immaterial. Included in the
accompanying balance sheet at June 30, 2026 is a right-of-use asset of $ 89,462 and current and long-term operating lease liabilities of
$ 44,831 and $ 46,123 , respectively. The applicable discount rate utilized for this lease at commencement was 9.0 %.
On May 14, 2025 the Company entered into a seven-year
lease in South Portland, Maine with two five-year extension options. The extensions associated with the lease have been accounted with
the assumption that they will not be extended. Remaining minimum lease payments at June 30, 2026 total $ 1,046,762 . Total lease costs including
base rent and common area expenses was $ 179,638 and $ 0 during the fiscal year ended June 30, 2026 and 2025, respectively. The amount of
variable lease payments is immaterial. Included in the accompanying balance sheet at June 30, 2026 is a right-of-use asset of $ 522,098
and current and long-term operating lease liabilities of $ 71,291 and $ 706,328 , respectively. The applicable discount rate utilized for
this lease at commencement was 9.0 %.
On June 2, 2025 the Company entered into a seven-year
operating lease in Littleton, Massachusetts with two five-year extension options. The extensions associated with the lease have been accounted
with the assumption that they will not be extended. Remaining minimum lease payments at June 30, 2026 total $ 2,498,362 . Total lease costs
including base rent and common area expenses was $ 354,216 and $ 0 during the fiscal year ended June 30, 2026 and 2025, respectively. The
amount of variable lease payments is immaterial. Included in the accompanying balance sheet at June 30, 2026 is a right-of-use asset of
$ 1,689,306 and current and long-term operating lease liabilities of $ 209,378 and $ 1,694,125 , respectively. The applicable discount rate
utilized for this lease at commencement was 9.0 %.
The weighted average discount rate is 9.0 % at
June 30,2026 and 8.3 % June 30, 2025. The weighted average lease term is 6.4 years at June 30, 2026 and 2.4 years at June 30, 2025. As
the rates implicit in the Company’s leases are generally not readily determinable, the Company utilizes its incremental borrowing rate
to determine the present value of lease payments. The incremental borrowing rate represents the interest rate the Company would be required
to pay to borrow on a collateralized basis over a similar term in an amount equal to the lease payments. The Company estimates the incremental
borrowing rate using information available at the lease commencement date, including prevailing market interest rates, the Company’s credit
profile, and the term of the lease. In circumstances where the implicit rate is readily determinable, that rate is used instead of the
incremental borrowing rate.
F- 15
At June 30, 2026 future minimum lease payments
under the operating lease obligations are as follows:
Schedule of principal payments due on term loan note payable
Fiscal Year Ending June 30:
Operating Lease
2027
$ 555,198
2028
567,327
2029
535,107
2030
551,240
2031
567,784
Thereafter
867,155
Total Minimum Payments
3,643,811
Less: amount representing interest
871,735
Present value of minimum lease payments
2,772,076
Less: current portion
325,500
Future minimum long-term lease liability
$ 2,446,576
The Company’s three facilities in Gardner,
Massachusetts, which are used for offices, production and storage spaces, are leased primarily on a tenant-at-will basis. Rent expense
on these operating leases was $ 210,187 and $ 206,309 for the fiscal years ended June 30, 2026 and 2025, respectively.
(3)
STOCKHOLDERS’ EQUITY
(a)
Stock-Based Compensation Expense
The following table summarizes stock-based compensation
expense for the years ended June 30:
Schedule of stock-based compensation
expense
2026
2025
Cost of Goods Sold
$ 135,079
$ 154,559
Selling, General and Administrative Expenses
1,004,613
1,457,547
Stock Based Compensation Expense
$ 1,139,692
$ 1,612,106
As of June 30, 2026, the unrecognized compensation
costs related to options vesting in the future was $ 853,104 . No compensation has been capitalized because such amounts would have been
immaterial. There was no net income tax benefit recognized related to such compensation for the years ended June 30, 2026, or 2025, as
the Company is currently in a loss position. There were 233,353 stock options granted during the year ended June 30, 2026, and 520,000
stock options granted during the year ended June 30, 2025.
F- 16
The Company uses the Black-Scholes option-pricing
model as the most appropriate method for determining the estimated fair value for the stock awards. The Black-Scholes method of valuation
requires several assumptions: (1) the expected term of the stock award; (2) the expected future stock volatility over the expected term;
and (3) risk-free interest rate. The expected term represents the expected period of time the Company believes the options will be outstanding
based on historical information. Estimates of expected future stock price volatility are based on the historic volatility of the Company’s
common stock, and the risk-free interest rate is based on the U.S. Zero-Bond rate. The Company utilizes a forfeiture rate based on an
analysis of the Company’s actual experience. The fair value of options at date of grant was estimated with the following assumptions
for options granted in fiscal year 2026:
Schedule of fair value of option assumptions
Year Ended
June 30, 2026
June 30, 2025
Assumptions:
Option life
6.25 years
6.25 years
Risk-free interest rate
3.88 - 4.19 %
4.02 - 4.52 %
Weighted average stock volatility
80.53 %
98.12 %
Dividend yield
0.0 %
0.0 %
Weighted average fair value of grants
$ 3.16
$ 3.84
(b)
Stock Option Plans
The type of share-based payments currently utilized
by the Company is stock options.
The Company has four stock option plans outstanding
as of June 30, 2026, namely the Precision Optics Corporation, Inc. 2022 Equity Incentive Plan (the “2022 Plan”), the Precision
Optics Corporation, Inc. 2021 Equity Incentive Plan (the “2021 Plan”), the Precision Optics Corporation, Inc. 2011 Equity
Incentive Plan (the “2011 Plan”) and the Precision Optics Corporation, Inc. 2006 Equity Incentive Plan (the “2006 Plan”).
Vesting periods under each of the Plans are at the discretion of the Board of Directors and typically average three years and in some
instances are subject to future performance criteria. Options under these Plans are granted at fair market value on the date of grant
and typically have an initial term of ten years from the date of grant, subject to certain cancellation provisions such as upon employment
termination. The Company has filed Registration Statements on Form S-8 with the Securities and Exchange Commission to register all shares
of common stock issuable under the 2022, 2021, 2011, and 2006 Plans.
On April 8, 2022, our Shareholders approved the
2022 Plan which provides eligible participants (certain employees, directors, consultants, etc.) the opportunity to receive a broad variety
of equity based and cash awards. A maximum of 1,318,333 shares of the Company’s common stock may be issued pursuant to stock options
or other awards under the 2022 Plan. At June 30, 2026, options for a total of 918,591 shares of common stock were outstanding and 399,742
shares of common stock were available for future grants under the 2022 Plan. The 2022 Plan permits the Board of Directors to authorize
and increase up to 5% of the then outstanding shares on an annual basis.
On May 10, 2021, our Board of Directors approved
the 2021 Plan which likewise authorizes a broad variety of equity based and cash awards. A maximum of 333,333 shares of the Company’s
common stock may be issued under the 2021 Plan. At June 30, 2026, options for a total of 248,989 shares of common stock were outstanding
under the 2021 Plan. No further shares may be issued from this plan.
The 2011 Plan and 2006 Plan likewise provided
for a broad variety of equity based and cash awards, but terminated in 2021 and 2016, respectively. At June 30, 2026, options for 432,325
shares of common stock were outstanding under the 2011 Plan, and none were outstanding under the 2006 Plan.
F- 17
The following tables summarize stock option activity
for the years ended June 30, 2026 and 2025:
Schedule of stock option activity
Options Outstanding
Number of
Shares
Weighted
Average
Exercise Price
Weighted
Average
Contractual
Life
Outstanding at June 30, 2024
1,357,735
$ 4.72
6.60 years
Grants
520,000
4.78
Exercised
( 129,329 )
2.79
Cancellations
( 124,830 )
5.34
Outstanding at June 30, 2025
1,623,576
$ 4.85
7.15 years
Grants
210,000
4.32
Exercised
( 46,666 )
1.47
Cancellations
( 127,001 )
5.58
Outstanding at June 30, 2026
1,659,909
$ 4.82
6.65 years
The aggregate intrinsic value of the Company’s
“in-the-money” outstanding and exercisable options as of June 30, 2026, was $ 974,540 and $ 833,438 , respectively.
(c)
Sale of Stock in February 2025
On February 19, 2025, the Company entered into
agreements with certain institutional and accredited investors for the sale and purchase of 1,272,500 unregistered shares of its common
stock, $0.01 par value at a purchase price of $4.00 per share, resulting in gross proceeds of approximately $ 5.1 million before deducting
placement agent commissions and other estimated offering expenses. The Company used the net proceeds from this placement for general working
capital needs and paydown of the Company’s line of credit.
(d)
Sale of Stock in March 2026
On March 27, 2026, the Company entered into an
underwriting agreement for a public offering of 2,777,777 shares of common stock at a price of $3.60 per share. The underwriter exercised
its over-allotment option in full at closing, resulting in 3,194,444 total shares issued. The offering closed on March 30, 2026. Net proceeds
after underwriting discounts, commissions, and offering expenses were $ 10,630,678 . The Company is using the net proceeds for working capital
and general corporate purposes.
(e)
Stock Warrants
In connection with the public offering that closed
on March 30, 2026, the Company issued to the underwriter warrants to purchase 159,722 shares of common stock at an exercise price of $ 4.21
per share. The warrants are immediately exercisable and expire on March 27, 2031. Each warrant is exercisable for one share of common
stock.
The warrants met the criteria for equity classification
under ASC 815-40 and were recorded within stockholders’ equity. The warrants are not subsequently remeasured as long as the conditions
for equity classification continue to be met.
The grant-date fair value of the warrants on the
issuance date of March 30, 2026 was approximately $ 342,687 , determined using a Black-Scholes option pricing model with the following assumptions:
stock price $ 4.20 , exercise price $ 4.21 , expected term of approximately 5 years, expected volatility of 54.8 %, risk-free interest rate
of 3.9 %, and dividend yield of 0 %. The fair value was recorded as an additional issuance cost and recognized as a reduction to additional
paid-in capital, with an offsetting credit to additional paid-in capital — warrants outstanding. The net impact on total stockholders’
equity was zero.
As of June 30, 2026, all 159,722 warrants remain
outstanding and unexercised.
F- 18
(4)
INCOME TAXES
The Company has identified its federal tax return
and its state tax return in Massachusetts as “major” tax jurisdictions. The periods subject to examination for its federal
and state income tax returns are the years ended in 2018 and thereafter. The Company believes its income tax filing positions and deductions
will be sustained on audit and it does not anticipate any adjustments that would result in a material change to its financial position.
Therefore, no liabilities for uncertain income tax positions have been recorded.
The provision for income taxes in the accompanying
consolidated statements of operations consists of the state income tax liability of $ 4,958 and $ 1,936 for the years ended June 30, 2026,
and 2025.
A reconciliation of the federal statutory rate
to the Company’s effective tax rate for the fiscal years ended June 30, 2026 and 2025 is as follows:
Schedule of effective income tax rate reconciliation
Year Ended June 30, 2026
Income tax expense (benefit) at federal statutory rate
$ ( 762,277 )
( 21.0 )%
Increase (decrease) in tax resulting from:
State taxes, net of federal benefit (1)
( 229,409 )
( 6.3 )%
Change in valuation allowance (2)
702,542
19.3 %
Stock based compensation
311,364
8.6 %
Nondeductible items
( 17,262 )
( 0.5 )%
Effective tax rate
$ 4,958
$ 0.1 %
Year Ended June 30, 2025
Income tax expense (benefit) at federal statutory rate
$ ( 1,213,852 )
( 21.0 )%
Increase (decrease) in tax resulting from:
State taxes, net of federal benefit (1)
( 365,312 )
( 6.3 )%
Change in valuation allowance (2)
1,204,859
20.8 %
Stock based compensation
398,983
6.9 %
Nondeductible items
( 22,742 )
( 0.4 )%
Effective tax rate
$ 1,936
$ 0.0 %
(1) State taxes in Massachusetts and California make up the majority (greater than 50%) of this category.
(2) During the fiscal year ended June
30, 2026 and June 30, 2025, we recorded $ 702,542 and $ 1,204,859 tax expense related to the increase in the valuation allowance for capital
losses generated during the year.
F- 19
The components of deferred tax assets and liabilities
at June 30, 2026 and 2025 are approximately as follows:
Schedule of components of deferred tax assets and liabilities
2026
2025
Deferred tax assets:
Net operating loss carry forwards
$ 6,165,000
$ 4,854,000
Tax credit carry forwards
501,000
338,000
Reserves and accruals not yet deducted for tax purposes
161,800
778,000
Total deferred tax assets
6,827,800
5,970,000
Valuation allowance
( 6,827,800 )
( 5,970,000 )
Net deferred tax asset
$ –
$ –
The Company has provided a valuation allowance
to reduce the net deferred tax asset to an amount the Company believes is “more likely than not” to be realized.
At June 30, 2026, the Company had federal and
state net operating loss carry forwards of approximately $ 25,468,000 and $ 13,179,000 , respectively, which will, if not used, expire at
various dates beginning in fiscal year 2027.
(5)
PROFIT SHARING PLAN
The Company has a defined contribution 401(k)
profit sharing plan. Employer profit sharing and matching contributions to the plan are discretionary. No employer profit sharing or matching
contributions were made to the plan in fiscal years 2026 and 2025.
(6)
CAPTIVE INSURANCE AND SELF-INSURED RISKS
Effective June 1, 2026, the Company established
a self-funded employee health insurance program and began participating in a group captive insurance arrangement. Under the program, the
Company is responsible for eligible employee healthcare claims, subject to stop-loss insurance coverage designed to limit exposure to
significant individual and aggregate claims.
The Company recognizes the cost of healthcare
claims in the period in which the underlying services are incurred, including an estimate for claims incurred but not reported (“IBNR”).
The estimated liability is based on available claims information, historical healthcare costs and other relevant information available
to management. Estimates are subject to uncertainty, and actual claims may differ from amounts estimated and recorded.
At June 30, 2026, the Company’s accrued liability
for healthcare claims, including IBNR, was approximately $ 70,000 .
F- 20
ITEM 9. CHANGES IN AND DISAGREEMENTS
WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.
None.